Cargando…
Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
OBJECTIVE: Evaluate the effect of sotagliflozin, a dual inhibitor of sodium glucose cotransporter (SGLT) 1 and 2, on arterial stiffness in patients with type 1 diabetes (T1D) treated with sotagliflozin as adjunct to optimized insulin therapy. METHODS: In this post hoc analysis, indirect markers of a...
Autores principales: | Rodbard, Helena W, Giaccari, Andrea, Cariou, Bertrand, Garg, Satish, Davies, Michael J, Seth, Kiernan, Sawhney, Sangeeta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481733/ https://www.ncbi.nlm.nih.gov/pubmed/33611925 http://dx.doi.org/10.1177/1479164121995928 |
Ejemplares similares
-
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020) -
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
por: Baker, Claire, et al.
Publicado: (2019) -
The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
por: Sridhar, Vikas S., et al.
Publicado: (2023) -
Validating the Safe and Effective Use of a Neurorehabilitation System (InTandem) to Improve Walking in the Chronic Stroke Population: Usability Study
por: Smayda, Kirsten Elisabeth, et al.
Publicado: (2023) -
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)